Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program.

Arsenault BJ, Pelletier-Beaumont E, Alméras N, Tremblay A, Poirier P, Bergeron J, Després JP.

Atherosclerosis. 2014 Oct;236(2):321-6. doi: 10.1016/j.atherosclerosis.2014.07.010. Epub 2014 Jul 26.

PMID:
25128757
2.

Plasma proprotein convertase subtilisin/kexin type 9 is associated with Lp(a) in type 2 diabetic patients.

Nekaies Y, Baudin B, Kelbousi S, Sakly M, Attia N.

J Diabetes Complications. 2015 Nov-Dec;29(8):1165-70. doi: 10.1016/j.jdiacomp.2015.08.003. Epub 2015 Aug 10.

PMID:
26412029
3.

Cardiometabolic risk improvement in response to a 3-yr lifestyle modification program in men: contribution of improved cardiorespiratory fitness vs. weight loss.

Borel AL, Nazare JA, Baillot A, Alméras N, Tremblay A, Bergeron J, Poirier P, Després JP.

Am J Physiol Endocrinol Metab. 2017 Apr 1;312(4):E273-E281. doi: 10.1152/ajpendo.00278.2016. Epub 2016 Dec 27.

PMID:
28028035
4.

The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.

Wassef H, Bissonnette S, Saint-Pierre N, Lamantia V, Cyr Y, Chrétien M, Faraj M.

J Clin Lipidol. 2015 Sep-Oct;9(5):664-75. doi: 10.1016/j.jacl.2015.06.012. Epub 2015 Jul 2.

PMID:
26350813
5.

Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.

Guardiola M, Plana N, Ibarretxe D, Cabré A, González M, Ribalta J, Masana L.

Clin Sci (Lond). 2015 Jun;128(12):877-82. doi: 10.1042/CS20140832.

PMID:
25649668
6.

Impact of a 1-year lifestyle modification program on plasma lipoprotein and PCSK9 concentrations in patients with coronary artery disease.

Boyer M, Lévesque V, Poirier P, Marette A, Mathieu P, Després JP, Larose É, Arsenault BJ.

J Clin Lipidol. 2016 Nov - Dec;10(6):1353-1361. doi: 10.1016/j.jacl.2016.08.014. Epub 2016 Sep 2.

PMID:
27919352
7.

Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial.

Bjermo H, Iggman D, Kullberg J, Dahlman I, Johansson L, Persson L, Berglund J, Pulkki K, Basu S, Uusitupa M, Rudling M, Arner P, Cederholm T, Ahlström H, Risérus U.

Am J Clin Nutr. 2012 May;95(5):1003-12. doi: 10.3945/ajcn.111.030114. Epub 2012 Apr 4.

8.

A semi-automated mass spectrometric immunoassay coupled to selected reaction monitoring (MSIA-SRM) reveals novel relationships between circulating PCSK9 and metabolic phenotypes in patient cohorts.

Gauthier MS, Pérusse JR, Awan Z, Bouchard A, Tessier S, Champagne J, Krastins B, Byram G, Chabot K, Garneau P, Rabasa-Lhoret R, Faubert D, Lopez MF, Seidah NG, Coulombe B.

Methods. 2015 Jun 15;81:66-73. doi: 10.1016/j.ymeth.2015.03.003. Epub 2015 Mar 11.

PMID:
25770357
9.
10.

Association of plasma small dense LDL cholesterol with PCSK9 levels in patients with angiographically proven coronary artery disease.

Zhang Y, Xu RX, Li S, Zhu CG, Guo YL, Sun J, Li JJ.

Nutr Metab Cardiovasc Dis. 2015 Apr;25(4):426-33. doi: 10.1016/j.numecd.2015.01.006. Epub 2015 Feb 2.

PMID:
25770756
11.

Improvement in insulin sensitivity following a 1-year lifestyle intervention program in viscerally obese men: contribution of abdominal adiposity.

Borel AL, Nazare JA, Smith J, Alméras N, Tremblay A, Bergeron J, Poirier P, Després JP.

Metabolism. 2012 Feb;61(2):262-72. doi: 10.1016/j.metabol.2011.06.024. Epub 2011 Aug 23.

PMID:
21864868
12.

Visceral and not subcutaneous abdominal adiposity reduction drives the benefits of a 1-year lifestyle modification program.

Borel AL, Nazare JA, Smith J, Alméras N, Tremblay A, Bergeron J, Poirier P, Després JP.

Obesity (Silver Spring). 2012 Jun;20(6):1223-33. doi: 10.1038/oby.2011.396. Epub 2012 Jan 19.

13.

Adiposity blunts the positive relationship of thyrotropin with proprotein convertase subtilisin-kexin type 9 levels in euthyroid subjects.

Kwakernaak AJ, Lambert G, Muller Kobold AC, Dullaart RP.

Thyroid. 2013 Feb;23(2):166-72. doi: 10.1089/thy.2012.0434.

14.

Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.

Constantinides A, Kappelle PJ, Lambert G, Dullaart RP.

Arch Med Res. 2012 Jan;43(1):11-4. doi: 10.1016/j.arcmed.2012.01.001. Epub 2012 Jan 31.

PMID:
22300679
15.

Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects.

Kwakernaak AJ, Lambert G, Dullaart RP.

Clin Biochem. 2012 Nov;45(16-17):1522-4. doi: 10.1016/j.clinbiochem.2012.07.002. Epub 2012 Jul 15.

PMID:
22809551
16.

Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.

Brouwers MC, Konrad RJ, van Himbergen TM, Isaacs A, Otokozawa S, Troutt JS, Schaefer EJ, van Greevenbroek MM, Stalenhoef AF, de Graaf J.

Nutr Metab Cardiovasc Dis. 2013 Nov;23(11):1115-21. doi: 10.1016/j.numecd.2012.11.008. Epub 2013 Jan 18.

PMID:
23333725
17.

Association of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) With Cardiovascular Risk in Primary Prevention.

Zhu YM, Anderson TJ, Sikdar K, Fung M, McQueen MJ, Lonn EM, Verma S.

Arterioscler Thromb Vasc Biol. 2015 Oct;35(10):2254-9. doi: 10.1161/ATVBAHA.115.306172. Epub 2015 Aug 20.

18.

Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients.

Kappelle PJ, Lambert G, Dullaart RP.

Atherosclerosis. 2011 Feb;214(2):432-5. doi: 10.1016/j.atherosclerosis.2010.10.028. Epub 2010 Nov 2.

PMID:
21122860
19.

ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.

Li S, Xu RX, Guo YL, Zhang Y, Zhu CG, Sun J, Li JJ.

Nutr Metab Cardiovasc Dis. 2015 Apr;25(4):411-7. doi: 10.1016/j.numecd.2014.10.015. Epub 2014 Nov 5.

PMID:
25466598
20.

Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents.

Baass A, Dubuc G, Tremblay M, Delvin EE, O'Loughlin J, Levy E, Davignon J, Lambert M.

Clin Chem. 2009 Sep;55(9):1637-45. doi: 10.1373/clinchem.2009.126987. Epub 2009 Jul 23.

Supplemental Content

Support Center